The rate of Utah women receiving mammograms is not what it used to be and not what it ought to be,” writes the editorial ...

Pancreatic cancer is one of the deadliest forms, but new research could one day lead to lives being saved. Researchers at UMass Chan Medical School in Worcester discovered that using something called ...

“It shows just how promising pelareorep treatment can be for extending the lives of breast cancer patients. This is further exemplified by the near doubling of the 2-year survival rate for patients ..

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population ... The ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive, ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...